Today the company reported a first-quarter loss as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue. The post Bristol...
https://www.pharmalive.com/bristol-myers-posts-quarterly-loss-lays-out-1-5-bln-cost-saving-plan/
By not only tackling high costs but also elevating patient experiences by enhancing efficiency and outcomes, this technology stands ready to revolutionize many aspects of the industry, says Globa...
https://www.pharmalive.com/generative-ai-advances-to-reshape-health-care/
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify th...
The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. The post M...
Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up ...
https://www.pharmalive.com/biogen-cost-cuts-drive-profit-beat-alzheimers-drug-sales-jump/
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates. The post Roche tri...
The company has resumed dismissing employees as part of an ongoing workforce reduction of about 10%. The post BMS initiates first round of layoffs in New Jersey appeared first on PharmaLive .
https://www.pharmalive.com/bms-initiates-first-round-of-layoffs-in-new-jersey/
Swiss drugmaker Novartis raised its full-year guidance on wider use of psoriasis and arthritis drug Cosentyx on Tuesday and said it had tapped the former boss of Bristol Myers Squibb to become i...
https://www.pharmalive.com/novartis-raises-guidance-after-beating-q1-expectations/
Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the chang...
https://www.pharmalive.com/sanofi-cuts-jobs-in-us-vaccines-division-as-part-of-restructuring/
Drug maker Vifor Pharma has offered to rectify its disparaging campaign against the closest rival to its blockbuster iron deficiency medicine Ferinject, EU antitrust regulators said on Friday, a ...
https://www.pharmalive.com/vifor-pharma-offers-to-rectify-anti-competitive-behavior-against-rival/